Perfluoroalkyl substances, metabolomic profiling, and alterations in glucose homeostasis among overweight and obese Hispanic children: A proof-of-concept analysis.


Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
05 2019
Historique:
received: 15 11 2018
revised: 23 01 2019
accepted: 18 02 2019
pubmed: 8 3 2019
medline: 31 10 2019
entrez: 8 3 2019
Statut: ppublish

Résumé

To examine the prospective associations between exposure to perfluoroalkyl substances (PFASs) and longitudinal measurements of glucose metabolism in high-risk overweight and obese Hispanic children. Forty overweight and obese Hispanic children (8-14 years) from urban Los Angeles underwent clinical measures and 2-hour oral glucose tolerance tests (OGTT) at baseline and a follow-up visit (range: 1-3 years after enrollment). Baseline plasma perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), perfluorohexane sulfonic acid (PFHxS), and the plasma metabolome were measured by liquid-chromatography with high-resolution mass spectrometry. Multiple linear regression models were used to assess the association between baseline PFASs and changes in glucose homeostasis over follow-up. A metabolome-wide association study coupled with pathway enrichment analysis was performed to evaluate metabolic dysregulation associated with plasma PFASs concentrations. We performed a structural integrated analysis aiming to characterize the joint impact of all factors and to identify latent clusters of children with alterations in glucose homeostasis, based on their exposure and metabolomics profile. Each ln (ng/ml) increase in PFOA and PFHxS concentrations was associated with a 30.6 mg/dL (95% CI: 8.8-52.4) and 10.2 mg/dL (95% CI: 2.7-17.7) increase in 2-hour glucose levels, respectively. A ln (ng/ml) increase in PFHxS concentrations was also associated with 17.8 mg/dL increase in the glucose area under the curve (95% CI: 1.5-34.1). Pathway enrichment analysis showed significant alterations of lipids (e.g., glycosphingolipids, linoleic acid, and de novo lipogenesis), and amino acids (e.g., aspartate and asparagine, tyrosine, arginine and proline) in association to PFASs exposure. The integrated analysis identified a cluster of children with increased 2-h glucose levels over follow up, characterized by increased PFAS levels and altered metabolite patterns. This proof-of-concept analysis shows that higher PFAS exposure was associated with dysregulation of several lipid and amino acid pathways and longitudinal alterations in glucose homeostasis in Hispanic youth. Larger studies are needed to confirm these findings and fully elucidate the underlying biological mechanisms.

Identifiants

pubmed: 30844580
pii: S0160-4120(18)32675-8
doi: 10.1016/j.envint.2019.02.047
pmc: PMC6555482
mid: NIHMS1027698
pii:
doi:

Substances chimiques

Alkanesulfonic Acids 0
Amino Acids 0
Caprylates 0
Environmental Pollutants 0
Fluorocarbons 0
Lipids 0
perfluorooctanoic acid 947VD76D3L
perfluorooctane sulfonic acid 9H2MAI21CL
perflexane FX3WJ41CMX
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

445-453

Subventions

Organisme : NIEHS NIH HHS
ID : K99 ES027870
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES007048
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK059211
Pays : United States
Organisme : NIEHS NIH HHS
ID : U2C ES026560
Pays : United States
Organisme : NIEHS NIH HHS
ID : F32 ES029828
Pays : United States
Organisme : NIEHS NIH HHS
ID : R00 ES027870
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107205
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES019776
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA196569
Pays : United States
Organisme : NIEHS NIH HHS
ID : R00 ES027853
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES000002
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES012870
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES028903
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES016813
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA140561
Pays : United States
Organisme : NIH HHS
ID : S10 OD018006
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Lancet Diabetes Endocrinol. 2018 Jan;6(1):69-80
pubmed: 28847479
J Biol Chem. 2001 Oct 12;276(41):38052-60
pubmed: 11498541
BMC Bioinformatics. 2013 Jan 16;14:15
pubmed: 23323971
Environ Health Perspect. 2018 Mar 01;126(3):037001
pubmed: 29498927
Diabetes Care. 2003 Jul;26(7):2094-9
pubmed: 12832319
Diabetes. 2017 Jul;66(7):1789-1796
pubmed: 28137791
Nat Med. 2011 Apr;17(4):448-53
pubmed: 21423183
Biochem Biophys Res Commun. 2015 May 8;460(3):491-6
pubmed: 25843796
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
J Clin Endocrinol Metab. 2015 Mar;100(3):E463-8
pubmed: 25423564
Lancet Diabetes Endocrinol. 2014 Jan;2(1):65-75
pubmed: 24622670
Adv Exp Med Biol. 2011;721:99-119
pubmed: 21910085
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Trends Endocrinol Metab. 2018 Mar;29(3):178-190
pubmed: 29290500
Arch Intern Med. 2003 Jun 9;163(11):1306-16
pubmed: 12796066
J Expo Sci Environ Epidemiol. 2019 Mar;29(2):196-205
pubmed: 30185940
Nat Rev Endocrinol. 2011 Jun;7(6):346-53
pubmed: 21467970
Environ Toxicol. 2013 Sep;28(9):532-42
pubmed: 23983163
Sci Rep. 2016 Apr 01;6:23963
pubmed: 27032815
Adv Nutr. 2011 Nov;2(6):445-56
pubmed: 22332087
Diabetes. 2001 Nov;50(11):2444-50
pubmed: 11679420
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
N Engl J Med. 2017 Jul 20;377(3):301
pubmed: 28723318
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
Diabetes Care. 2009 Apr;32(4):702-7
pubmed: 19114613
Reprod Toxicol. 2017 Mar;68:3-33
pubmed: 27760374
Diabetes. 2013 Feb;62(2):639-48
pubmed: 23043162
J Steroid Biochem Mol Biol. 2011 May;125(1-2):143-7
pubmed: 21237268
Epidemiology. 2011 Sep;22(5):745
pubmed: 21811114
Islets. 2012 May-Jun;4(3):177-87
pubmed: 22847494
PLoS One. 2014 Jan 31;9(1):e87137
pubmed: 24498028
Nat Rev Endocrinol. 2018 Aug;14(8):449-451
pubmed: 29970917
Am J Physiol. 1979 Jun;236(6):E667-77
pubmed: 443421
Mol Cell Endocrinol. 2009 May 25;304(1-2):97-105
pubmed: 19433254
Environ Int. 2016 Mar;88:60-66
pubmed: 26720637
Environ Health Perspect. 2012 May;120(5):668-73
pubmed: 22306490
Environ Health Perspect. 2017 Nov 13;125(11):117004
pubmed: 29135438
Public Health Rep. 2014 Nov-Dec;129(6):482-5
pubmed: 25364048
Bioinformatics. 2009 Aug 1;25(15):1930-6
pubmed: 19414529
Metabolomics. 2013 Mar;9(1 Suppl):S132-S143
pubmed: 26229523
J Proteome Res. 2017 Aug 4;16(8):2743-2751
pubmed: 28621139
Am J Clin Nutr. 2015 Jan;101(1):153-63
pubmed: 25527759
Environ Pollut. 2018 Jan;232:73-79
pubmed: 28923343
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
Diabetes Care. 2013 Mar;36(3):648-55
pubmed: 23129134
PLoS Comput Biol. 2013;9(7):e1003123
pubmed: 23861661
PLoS One. 2014 Jan 17;9(1):e85082
pubmed: 24465478
Anal Chem. 2013 Dec 17;85(24):11725-31
pubmed: 24147600
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes Care. 2016 Oct;39(10):1745-51
pubmed: 27489335
Sci Total Environ. 2018 Jun 1;625:566-574
pubmed: 29291571
J Clin Endocrinol Metab. 2004 Jan;89(1):207-12
pubmed: 14715851
Toxicol Sci. 2015 Dec;148(2):531-43
pubmed: 26358001
J Nutr. 2005 Jun;135(6 Suppl):1539S-46S
pubmed: 15930466
Environ Health Perspect. 2017 Mar;125(3):481-487
pubmed: 27586368

Auteurs

Tanya L Alderete (TL)

Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, United States. Electronic address: tanya.alderete@colorado.edu.

Ran Jin (R)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: jinr@usc.edu.

Douglas I Walker (DI)

Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address: douglas.walker@mssm.edu.

Damaskini Valvi (D)

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States. Electronic address: dvalvi@hsph.harvard.edu.

Zhanghua Chen (Z)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: zhanghuc@usc.edu.

Dean P Jones (DP)

Clinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States. Electronic address: dpjones@emory.edu.

Cheng Peng (C)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: chengpen@usc.edu.

Frank D Gilliland (FD)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: gillilan@usc.edu.

Kiros Berhane (K)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: kiros@usc.edu.

David V Conti (DV)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: dconti@med.usc.edu.

Michael I Goran (MI)

Department of Pediatrics, Children's Hospital of Los Angeles, The Saban Research Institute, United States. Electronic address: goran@usc.edu.

Lida Chatzi (L)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: chatzi@usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH